Josep Bassaganya-Riera, president and CEO of Landos Biopharma Inc., told BioWorld that the firm's lead compound, BT-11, in mouse models is "acting as a double-barrel shotgun" against inflammatory bowel disease (IBD), in both Crohn's disease and ulcerative colitis.